CORRESP Filing
KIORA PHARMACEUTICALS INC
Date: Sept. 17, 2025 · CIK: 0001372514 · Accession: 0001372514-25-000074
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290263
Letter
Document Kiora Pharmaceuticals, Inc. 169 Saxony Road, Suite 212 Encinitas, California 92024 September 17, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “ Company ”) Registration Statement on Form S-3 File No. 333-290263 Request for Acceleration Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “ Commission ”) of the effective date of the Registration Statement on Form S-3 (File No. 333-290263) (the “ Registration Statement ”) of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on September 19, 2025, or as soon as practicable thereafter. The Company respectfully requests that it be notified of such effectiveness by a telephone call to Robert A. Petitt of Blank Rome LLP at (617) 415-1219 and that such effectiveness also be confirmed in writing. If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (858) 224-9600 or our attorney, Robert A. Petitt at the number above. Thank you for your assistance. Very truly yours, Kiora Pharmaceuticals, Inc. By: /s/ Brian M. Strem, Ph.D. Name: Brian M. Strem, Ph.D. Title: President and Chief Executive Officer cc: Robert A. Petitt, Esq., Blank Rome LLP
Show Raw Text
CORRESP 1 filename1.htm Document Kiora Pharmaceuticals, Inc. 169 Saxony Road, Suite 212 Encinitas, California 92024 September 17, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “ Company ”) Registration Statement on Form S-3 File No. 333-290263 Request for Acceleration Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “ Commission ”) of the effective date of the Registration Statement on Form S-3 (File No. 333-290263) (the “ Registration Statement ”) of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on September 19, 2025, or as soon as practicable thereafter. The Company respectfully requests that it be notified of such effectiveness by a telephone call to Robert A. Petitt of Blank Rome LLP at (617) 415-1219 and that such effectiveness also be confirmed in writing. If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (858) 224-9600 or our attorney, Robert A. Petitt at the number above. Thank you for your assistance. Very truly yours, Kiora Pharmaceuticals, Inc. By: /s/ Brian M. Strem, Ph.D. Name: Brian M. Strem, Ph.D. Title: President and Chief Executive Officer cc: Robert A. Petitt, Esq., Blank Rome LLP